Last €0.91 EUR
Change Today +0.007 / 0.78%
Volume 0.0
PTNA On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 2:20 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

palatin technologies inc (PTNA) Snapshot

Open
€0.91
Previous Close
€0.90
Day High
€0.91
Day Low
€0.91
52 Week High
03/24/14 - €1.03
52 Week Low
10/22/13 - €0.34
Market Cap
35.7M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
39.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PALATIN TECHNOLOGIES INC (PTNA)

palatin technologies inc (PTNA) Related Bloomberg News

View More Bloomberg News

palatin technologies inc (PTNA) Related Businessweek News

No Related Businessweek News Found

palatin technologies inc (PTNA) Details

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. Its clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase III clinical trials for the treatment of female sexual dysfunction. The company’s drug development programs comprise PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase 1 clinical trial for the treatment of cardiovascular and pulmonary indications; melanocortin receptor-based compounds for treatment of obesity; and Melanocortin receptor-1 agonist peptides for treatment of dermatologic and inflammatory disease indications. Palatin Technologies, Inc. has research collaboration and license agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.

20 Employees
Last Reported Date: 09/27/13
Founded in 1986

palatin technologies inc (PTNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $436.8K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $394.2K
Compensation as of Fiscal Year 2013.

palatin technologies inc (PTNA) Key Developments

Palatin Technologies, Inc. Announces Positive Data from Phase IIb Female Sexual Dysfunction Trial

Palatin Technologies Inc. announced new analyses from its Phase IIb clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD). Bremelanotide is a first-in-class, investigative melanocortin agonist being developed for treatment of female sexual dysfunction (FSD). In one abstract, responder analyses showed bremelanotide had a statistically significant increase in the percentage of women whose total score on the Female Sexual Function Index (FSFI) - a measure of overall sexual functioning - improved: 69% for 1.75 mg versus 46% for placebo (p<0.05). In addition, a significantly higher percentage of women on bremelanotide versus placebo achieved at least one satisfying sexual event (SSE): 55% for 1.75 mg versus 37% for placebo (p<0.05). A second abstract, presenting data from the episodic questionnaire, Female Sexual Encounter Profile - Revised (FSEP-R), demonstrated greater mean increases in SSEs within 24 hours of dosing with bremelanotide 1.75 mg (mean increase: 0.7; p=0.0443) versus placebo (mean increase: 0.1). As-needed administration of bremelanotide 1.75 mg versus placebo also demonstrated episodic increases in levels of desire (0.4 vs. 0.0, respectively) and in the women's satisfaction with their levels of desire (0.6 vs. 0.1, respectively). In a third abstract, data collected from the Women's Inventory of Treatment Satisfaction (WITS-9) showed women who completed treatment were significantly more satisfied with bremelanotide 1.75 mg (0.77; p=0.0204) versus placebo (0.17).

Palatin Technologies, Inc. Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

Palatin Technologies Inc. presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD). The data from three clinical abstracts were presented Saturday, February 22, 2014 at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in San Diego. Bremelanotide is an investigative melanocortin agonist being developed for treatment of female sexual dysfunction (FSD). In one abstract, responder analyses showed bremelanotide had a statistically significant increase in the percentage of women whose total score on the Female Sexual Function Index (FSFI) -- a measure of overall sexual functioning -- improved: 69% for 1.75 mg versus 46% for placebo (p<0.05). In addition, a significantly higher percentage of women on bremelanotide versus placebo achieved at least one satisfying sexual event (SSE): 55% for 1.75 mg versus 37% for placebo (p<0.05). A second abstract, presenting data from the episodic questionnaire, Female Sexual Encounter Profile -- Revised (FSEP-R), demonstrated greater mean increases in SSEs within 24 hours of dosing with bremelanotide 1.75 mg (mean increase: 0.7; p=0.0443) versus placebo (mean increase: 0.1). As-needed administration of bremelanotide 1.75 mg versus placebo also demonstrated episodic increases in levels of desire (0.4 vs. 0.0, respectively) and in the women's satisfaction with their levels of desire (0.6 vs. 0.1, respectively). In a third abstract, data collected from the Women's Inventory of Treatment Satisfaction (WITS-9) showed women who completed treatment were significantly more satisfied with bremelanotide 1.75 mg (0.77; p=0.0204) versus placebo (0.17).(3) Bremelanotide was well-tolerated during the trial. The most common types of treatment-emergent adverse events reported more frequently in the bremelanotide arms were facial flushing, nausea and emesis, which were mainly mild-to-moderate in severity. The study dosed 394 patients. Adverse events that most commonly led to discontinuation were nausea and emesis. No serious adverse events were attributed to bremelanotide during the trial. Palatin anticipates commencing enrolling patients in Phase 3 clinical trials in the second half of this year. The objectives of the Phase 2b trial were to demonstrate and identify safe and effective SC fixed doses of bremelanotide intended for on-demand use in premenopausal females with FSD, and to define endpoint measurements to support transition to Phase 3 clinical studies and activities.

Palatin Technologies Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 03:30 PM

Palatin Technologies Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 03:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Carl Spana, Co-Founder, Chief Executive Officer, President, Director and Director of Rhomed Incorporated.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTNA:GR €0.91 EUR +0.007

PTNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTNA.
View Industry Companies
 

Industry Analysis

PTNA

Industry Average

Valuation PTNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PALATIN TECHNOLOGIES INC, please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.